Related references
Note: Only part of the references are listed.Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Kai Yuan et al.
ACTA PHARMACEUTICA SINICA B (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer
Yuhao Ren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Optimization of 4,6-Disubstituted Pyrido[3,2-d]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth
Yu Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
Shipeng He et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening
Kai Yuan et al.
FUTURE MEDICINAL CHEMISTRY (2020)
Perspective Rational Cancer Treatment Combinations: An Urgent Clinical Need
Julia Boshuizen et al.
MOLECULAR CELL (2020)
Clinical Development of BRAF plus MEK Inhibitor Combinations
Vivek Subbiah et al.
TRENDS IN CANCER (2020)
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
K. M. Heinhuis et al.
ANNALS OF ONCOLOGY (2019)
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Leila Dardaei et al.
NATURE MEDICINE (2018)
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation
Solomon Tadesse et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat
Lianbin Yao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma
Gao Guo et al.
NATURE NEUROSCIENCE (2017)
Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6
Iris Z. Uras et al.
BLOOD (2016)
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer
Hanlin Zeng et al.
CANCER CELL (2016)
Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines
Eugene Guorong Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado et al.
NATURE (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity
Chenyi Yang et al.
CANCER RESEARCH (2015)
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
Pawel K. Mazur et al.
NATURE MEDICINE (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero et al.
NATURE REVIEWS CANCER (2015)
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
Erika K. Keeton et al.
BLOOD (2014)
Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia
Lisa S. Chen et al.
BLOOD (2011)
Share Paper
